NCT03217071View on ClinicalTrials.gov

Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 4, 2017

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Pembrolizumab

All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.

RADIATION

stereotactic radiation therapy (SRT)

Patients in Cohort 2 of the Safety run-in and patients in the expansion cohort who are randomized to the 'pembrolizumab +radiation arm' will receive one dose of SRT within 1 week (+/- 3 days) following the second administration of pembrolizumab.

PROCEDURE

Surgery (Non-interventional, standard of care)

Standard of care surgery to remove cancer

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Sue Yom

OTHER

NCT03217071 - Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter